Free access to Zolgensma curbed, says Novartis
pharmaphorum
JANUARY 9, 2023
” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 million in the US and just under €2 million in Europe, which the company says is justified by its dramatic benefits when given as a one-shot therapy to patients with SMA. Pause in UK access.
Let's personalize your content